bacteremia

Armata Advances AP-SA02 Toward Phase III Bacteremia Trial

LOS ANGELES, July 20, 2026 Armata Pharmaceuticals, Inc. has announced significant clinical, regulatory, manufacturing, and operational progress supporting the...

By cGxPwire Editor
July 21, 2026

.Clinical

Armata Gains FDA Fast Track for AP-SA02 Therapy

LOS ANGELES, May 7, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast...

By cGxPwire Editor
May 8, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

bacteremia

Armata Advances AP-SA02 Toward Phase III Bacteremia Trial

Armata Gains FDA Fast Track for AP-SA02 Therapy